Target intelligence / Profile preview

Human immunoglobulin G heavy chain hinge region (IgG hinge)

Target
IgG hinge
Molecular classification
Immunoglobulin domain, Protein region
01

Overview

The Human immunoglobulin G (IgG) heavy chain hinge region is a specialized, flexible amino acid sequence located between the CH1 and CH2 constant domains of the IgG heavy chain [1]. Its primary biological function is to provide the Fab arms with the necessary mobility to bind bivalently to antigens at varying distances and orientations [2]. Structurally, the hinge region contains the inter-chain disulfide bridges that covalently link the two heavy chains, maintaining the overall Y-shaped architecture of the antibody [1]. In clinical medicine, this region is a critical target for Imlifidase (IdeS), a cysteine protease that specifically cleaves the IgG hinge to separate the Fab fragments from the Fc region [3]. This cleavage effectively abolishes the antibody's ability to trigger complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) [4]. Consequently, the IgG hinge region is a focal point for therapeutic intervention in antibody-mediated rejection during organ transplantation and in severe autoimmune diseases [3, 5]. Citations: [1] UniProt Consortium, P01857; [2] Roux, K. H., et al. (1997) J Immunol; [3] Jordan, S. C., et al. (2017) N Engl J Med; [4] Hansson, S., et al. (2020) Curr Opin Organ Transplant; [5] Lonze, B. E., et al. (2018) Am J Transplant.

Other names
IgG hinge regionImmunoglobulin G hingeHinge domain of IgGIgG heavy chain hinge
02

Mechanism of action

Proteolytic cleavage of the hinge region at a specific amino acid sequence (e.g., Gly-Pro-Ser-Val-Phe-Leu-Phe) to separate the antigen-binding Fab fragments from the effector-mediating Fc fragment, thereby neutralizing antibody effector functions [3, 4].

03

Biological functions

Antigen binding flexibilityEffector function modulationComplement activationFc receptor bindingHeavy chain dimerization
04

Disease associations

Autoimmune diseaseGraft rejectionAntibody-mediated rejectionGoodpasture syndrome
05

Safety considerations

Increased risk of infection due to transient hypogammaglobulinemiaImmunogenicity of the therapeutic enzyme (e.g., anti-drug antibodies)Transient depletion of protective vaccine-induced antibodies [4, 5]
06

Interacting drugs

Imlifidase
07

Biomarkers

Total IgG levelsDonor-specific antibodies (DSA)IgG cleavage fragmentsAnti-HLA antibody titers

Beyond the preview

Go deeper on Human immunoglobulin G heavy chain hinge region (IgG hinge).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunoglobulin G heavy chain hinge region (IgG hinge).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call